Tag: Medicine

Immunity Memory Cells Stay Stable Over Time After Recovery From COVID-19

Written by AUFTAU on 13 October 2020. Posted in Newsroom.

Researchers of Tel Aviv University examined blood samples from 60 patients at Hasharon Hospital who had recovered from Corona, and found that memory B cells specific to the virus remain stable over time, but concurrently the antibodies in the blood decrease within just a few months. This finding prompted the researchers to raise the possibility that in the event of re-infection with the virus, symptomatic illness will be insignificant. The research was conducted by Dr. Yariv Wine of Tel Aviv University’s Shmunis School of Biomedicine and Cancer Research, and led by post-doctoral fellow Anna Vaisman-Mentesh, together with Dr. Dror Dicker, Director of the Department of Internal Medicine “D” at Hasharon Hospital, and department’s team.

They don’t forget so quickly

Since the SARS-CoV-2 is a new virus, there is as yet no data on immune memory over time among those recovered from the virus. In the current research, Dr. Wine and team checked the level of antibodies, as well as the B cell count in their group of subjects. As has been shown in other previous studies, the antibodies acting on the viral protein responsible for attaching itself to target cells in the host body, develop very quickly – but decay following recovery. In contrast, B cells, that remember the viral proteins and can efficiently reactivate upon reinfection, do not decline in recovered subjects over a period of six months.

“Corona is a serious illness and includes long-lasting side effects,” Dr. Wine explains. “For that reason, rehabilitation centers have been established for those recovering from Corona, such as the one at Hasharon Hospital, and it also enables us to continue examining blood samples even many months after recovery. From among the group of recovered patients who have volunteered to be part of the research, we collected blood samples at predetermined time intervals – 3 months after onset of disease, and again 3 months later. From the data thus gathered, we can say that over at least a 6 month time period, the subjects maintained a stable level of memory B cells specific to the viral protein. The significance of this is that if these subjects become re-infected, their immune system can quickly respond: B cells will create a secondary reaction which may prevent illness. On the other hand, due to the decay of the antibodies, those who have recovered can still be carriers of the virus, and perhaps also be able to infect others.”

Since the antibodies in the blood of those recovered from Corona decay with time, and in some cases even fall below detection threshold just 3 months after recovery, Dr. Wine and his team fear that serological surveys may be providing an inaccurate picture to decision-makers regarding spread of infection.

Concern over problem in reliability results in serological surveys

“Health organizations and the media talk a lot about serological surveys that check the level of antibodies in the blood, as a way of inferring the spread of disease in the population,” Dr. Wine says. “These surveys are very important, but in the light of the data on the decay of antibodies among recovered subjects, we might get a negative result when testing those who were infected in the past. If the antibodies are not maintained over time, and those who have recovered can still carry the virus and infect others, it is challenging to extrapolate from these surveys the breadth of infection spread in the population.”

Dr. Dicker adds that we are in a process of ongoing learning about Corona virus clinical illness when some recovered subjects still carry the virus. These findings add to our understanding of chronic illness from Corona and may shed light on future capabilities of the immune system of these recovered subjects.

Researchers Identified the Genetic Causes of Inherited Hearing Loss in the Jewish Population of Israel

Written by AUFTAU on 30 September 2020. Posted in Newsroom.

In the Jewish population of Israel, until now, seven genes were known to be involved in hearing loss. Now, thanks to a new study led by Zippora Brownstein, PhD, and Prof. Karen Avraham from the Sackler Faculty of Medicine at Tel Aviv University, the number of genes known to be responsible for inherited hearing loss in Israeli Jewish families is 32.

These results have immediate implications for genetic counseling for families with hearing loss and for care of children with hearing loss. The research was in cooperation with scientists from multiple Israeli universities and hospitals, and from the University of Washington in Seattle, the U.S. National Institutes of Health (NIH), Bethlehem University, the University of Iceland, and the University of Maryland. The researchers also identified a mutation in a gene not previously recognized to cause hearing loss in humans. This breakthrough research was published recently in the journal Clinical Genetics.

The 25^th gene

More than 150 genes are known to science to be involved in hearing loss. Genetic diagnoses for inherited hearing loss have previously been difficult, both world wide and in Jewish communities, because any one of so many different genes, and any of many mutations in each gene, could be the cause. Until now, mutations in only seven of the 150 genes had been detected among persons with hearing loss in the Jewish population of Israel. In the current study, which included 88 Israeli families with hearing loss, the researchers identified mutations in 25 additional genes.

Although 24 of the 25 genes are known to cause hearing loss in families worldwide, most of the specific mutations in Israeli Jewish families are newly observed and thus far known only the Jewish community. The 25^th gene, called ATOH1, was found for the first time to cause hearing loss in humans.

^{Organ of Corti of the inner ear labelled with antibodies to show sensory hair cells responsible for hearing. Photo Credit: Shahar Taiber & Prof. Karen Avraham}

“We know that ATOH1 has an important role in the ear,” explains Prof. Avraham, “without it, hair cells of the inner ear – the cells responsible for our hearing – cannot develop properly. Until now, a mutation in this gene was identified only in mice, and the mice had a hearing loss. We found a similar mutation in relatives with hearing loss in a large family in Israel – the first people in the world known to have a mutation in this gene. I believe we will find more families, both in Israel and abroad, with mutations in this gene that cause hearing loss. The goal is that with this information, new treatment possibilities for people with hearing loss will be developed – including gene therapy.”

Prof. Avraham adds: “We surveyed Jewish families throughout Israel with all types of hearing loss: from congenital to older age at onset, and from moderate to profound. Our survey exploited advanced gene sequencing technology, including a custom gene panel that we created, called HEar-Seq. This custom gene panel allowed us to simultaneously sequence all 150 genes known to be involved in hearing loss, and many “candidate genes” as well. HEar-Seq revealed the distribution of genes and their mutations responsible for hearing loss in all the Jewish communities that make up modern Israel. It led us to ATOH1.

Our discoveries have immediate implications for genetic counseling, which can enable families to prevent additional cases of hearing loss through pre-gestational genetic diagnosis and in-vitro fertilization. Also, for many families, treatment and rehabilitation for hearing loss can be tailored to the family’s specific mutation. The findings of this study allow doctors and audiologists in Israel to provide personally tailored treatment to patients with inherited hearing loss.”

The study was funded by the National Institute of Deafness and Communication Disorders of the U.S. National Institutes of Health, the Israel Precision Medicine Program of the Israel Science Foundation, the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, the Hedrich Charitable Trust, and travel grants from the University of Washington Virginia Bloedel Hearing Research Institute.

Prof. Karen Avraham

Zippora Brownstein, PhD

New Program Fosters Well-Rounded STEM Graduates

Written by AUFTAU on 17 September 2020. Posted in Newsroom.

Expansion of the Jack, Joseph and Morton Mandel Center for Humanities in STEM ushers in a new era in the Israeli university curriculum By Rafael Ben-Menashe Beginning in the next academic year, 1,500 incoming students in Engineering, Exact Sciences and Life Sciences will encounter a new opportunity in their studies: they will be able to take three Humanities courses as part of their regular degree requirements. The force behind this move – a first in Israel – is the Jack, Joseph and Morton Mandel Center for Humanities in STEM at TAU. “Students will experience dramatically different learning styles by switching between humanities and STEM subjects,” says Prof. Yochai Oppenheimer, a member of TAU’s Department of Hebrew Literature and Academic Head of the Mandel Center. He describes this change as “a refreshing jump into a pool for the mind” and says that, through the Mandel Center, TAU is embracing a global trend of incorporating liberal arts into science and technology curricula. The focus will be on introductory and survey courses that will instill essential skills of humanistic thought such as critical thinking, debating, writing, ethical analysis and more. Battling a worldwide trend Around the world, enrollment in the humanities has fallen over the last two decades while that of STEM has increased. At Tel Aviv University, the number of undergraduates at the Entin Faculty of Humanities dropped from 2,600 in 2003 to 1,600 in 2018, a reduction of 38% over 15 years. In response, the Jack , Joseph and Morton Mandel Foundation, under the leadership of the late Morton L. Mandel, pioneered the Program for Humanities in Engineering at TAU in 2016. Completely new on the Israeli academic landscape at the time, the Program allowed a group of 25 honors students to add a sizeable humanities module to their engineering studies. They were given generous scholarships along with personal mentors to guide them in course selection. The Program was a great success: Participants praised it and top tech companies expressed eagerness to hire graduates. Based on these positive results, in 2019 TAU established the Jack, Joseph and Morton Mandel Center for STEM and the Humanities to replicate the Jack, Joseph and Morton Mandel Program for Humanities in Engineering for outstanding Exact Sciences and Life Sciences students as well. The newest expansion of the initiative, toward the 2021-22 school year, will extend humanities offerings to all incoming STEM students at TAU. “The Mandel Center reinforces the humanities’ relevance to science and technology, nurturing well-rounded technological leaders in Israel. Presently the Israeli Council for Higher Education is considering duplicating the program at other Israeli universities,” says Oppenheimer. Welcoming uncertainty Students enrolled in Mandel Center-sponsored humanities courses say they provide a bonus, a break from the more regimented styles of thinking in STEM subjects. “In the sciences, we fear questions that don’t ultimately have definitive answers,” says Michal Levin, a fourth-year engineering student. “In the humanities, we are taught to embrace those types of questions.” Similarly, Ido Mellul, a first-year biology student, says: “The program has helped me better formulate philosophical questions in a scientific context. For example, I questioned my lecturers regarding applied ethics in the case of gene-editing technology,” he says. “This was something I didn’t think I could do before.” Levin also points to the Mandel Scholarship she received as a tremendous aid in her studies. “It eliminated the stress of finding work and financing my life while studying.” The courses offered through the Mandel Center cover philosophy, rhetoric, cultural studies, literature and history. “The idea behind the program immediately struck a chord with me,” says Amit Alkoni, a third-year engineering student. “I served in an engineering unit of the Intelligence Corps in the army, and my service helped me envision how effective evaluation of communication and ethics can expand my professional horizons.These are tools I ultimately acquired through studying the humanities.” Last year, shortly before his death, TAU conferred its highest honor, the degree of Doctor Philosophiae Honoris Causa, upon Morton Mandel, an entrepreneur and lifelong Israel supporter, for his visionary support of TAU. “The Mandel Foundation’s generosity has allowed TAU to rejuvenate the humanities, ensuring that TAU students benefit from this crucial school of thought, which in turn benefits Israeli society as a whole,” says TAU President Prof. Ariel Porat. Prof. Jehuda Reinharz, President and CEO of of the Jack, Joseph and Morton Mandel Foundation, adds: “We are delighted to collaborate with Tel Aviv University on this important venture. The combination of STEM subjects with humanities education is precisely the kind of preparation every student should have today and in the future before he/she enters the work force. Given the decline in humanistic education and values this is the time to have such interdisciplinary programs. Tel Aviv University is a pioneer in this far-sighted work across the disciplines, and I am quite certain that it will become a model for many other institutions in Israel and abroad.” Featured image: Mandel Scholars Amit Alkoni and Michal Levin. Photo: Moshe Bedarshi.

Google Awards Competitive Grant to Tel Aviv University for COVID-19 Research

Written by AUFTAU on 15 September 2020. Posted in Newsroom.

Targeting Melanoma

Written by AUFTAU on 10 September 2020. Posted in Newsroom.

Researchers at Tel Aviv University, led by Prof. Ronit Satchi-Fainaro from the Department of Physiology and Pharmacology at the Sackler Faculty of Medicine, developed an innovative nanotechnological drug delivery system that significantly enhances the effectiveness of treatment for the aggressive skin cancer melanoma. The nanocarrier is a biocompatible and biodegradable polymer, which comprises repeating units of glutamic acids (PGA- polyglutamic acid), packaging together two biological drugs belonging to different families with proven efficacy for the treatment of melanoma: BRAF inhibitors (Dabrafenib) and MEK inhibitors (Selumetinib, approved for use in children with NF1 – neurofibromatosis type I).

Prof. Satchi-Fainaro: “One of the major obstacles of the biological treatments is that after a while, the cancer cells develop resistance to the drugs. We assume that by precise delivery of two or more targeted drugs that will attack the cancer cells forcefully and simultaneously from different directions, we can delay or even prevent the acquisition of this drug-resistance.”

The research group included PhD students Evgeni Pisarevsky, Dr. Rachel Blau and Yana Epshtein from Prof. Satchi-Fainaro’s research laboratory at TAU’s Sackler School of Medicine. The paper was published as the cover article of the August 2020 issue of Advanced Therapeutics.

Prof. Satchi-Fainaro: “In this project, we looked for a solution to a problem often associated with drug cocktails: Today, most oncological treatments are administered in the form of cocktails of several medications; However, despite the fact that all drugs are administered to the patient simultaneously, they do not reach the tumor at the same time, due to differences in basic parameters – like how long they survive in the bloodstream (i.e. half-life), and the time it takes each drug to reach the tumor tissue. Thus, in most cases, the medications do not work concurrently, which prevents them from attaining optimal synergistic activity.”

Responding to these challenges, the researchers developed an innovative, efficient and biodegradable drug delivery system. Two biological drugs, known to be effective for the treatment of melanoma, Dabrafenib and Selumetinib, (inhibiting two different components – BRAF and MEK respectively – in the biological pathway which is over-activated in melanoma), were chosen, with the intention of delivering them jointly to the tumor by using a nanocarrier. The drug nanocarrier chosen for the task was PGA, a polymer of glutamic acid – one of nature’s most common amino acids. Developed in Prof. Satchi-Fainaro’s lab several years ago, the nanocarrier has already been tested successfully for treating pancreatic, breast and ovarian cancer in animal models.

In search of an optimal ratio

First, the researchers determined the optimal ratio between the two medications – based on levels and types of toxicity, as well as the resistance mechanism developed by cancer cells for each medication – to ultimately ensure maximum effectiveness, minimal toxicity and optimal synergistic activity. Another important advantage of joint delivery is reduced dosage: a much lower dose is required compared to each drug when administered independently.

The next step was using chemical modifications to enable bonding between the polymeric carrier and the chosen drugs. This combined system can travel through the body with total safety, inflicting no damage to healthy tissues. Upon reaching the cancer cells, the nanocarrier encounters proteins of the cathepsins enzyme family, which are highly activated in malignant tumors. The proteins degrade the polymer, releasing the drugs which become active and join forces to attack the tumor. Prof. Satchi-Fainaro: “It’s like several passengers riding in one cab and getting off together at the same address. They all arrive at the same destination, right at the same time.”

Promising results

Tested on a mouse model of melanoma, the new treatment showed promising results: The nanocarrier delivered the two drugs to the tumor and released them there simultaneously in quantities about 20 times greater than those that reach the tumor when similar doses of the same medications are administered independently. In addition, the therapeutic effect achieved by the drugs delivered by the nanocarrier lasted much longer – 2-2.5 times compared to control group and the group treated with free medications. According to the researchers, this means that the new platform enables much lower dosages – about one third of the dose required in regular drug cocktails, and the treatment as a whole is both safer and more effective. Also, if needed, the new approach allows for dosages that are much higher than the maximum dosage permissible in current methods, thereby enhancing the effectiveness of the treatment even further.

Prof. Satchi-Fainaro: “In this project, we developed an innovative drug delivery system for treating melanoma, delivering two proven medications and releasing them simultaneously at the tumor site. The treatment proved both safer and more effective than the same medications administered as a cocktail. Moreover, our new platform is highly modular and can be used for delivering a vast range of medications. We believe that its potential for enhancing therapeutics for different diseases is practically endless.”

The study was funded by the Israel Cancer Research Fund (ICRF), the European Research Council (ERC), Israel’s Ministry of Health (EuroNanoMed-II program), the Melanoma Research Alliance, the Morris Kahn 3D BioPrinting for Cancer Research Initiative and the Israel Science Foundation (ISF).

Featured image: Prof. Ronit Satchi-Fainaro

TAU Wins 3M Grant to Accelerate COVID-19 Vaccine Development

Written by AUFTAU on 10 September 2020. Posted in Newsroom.

Science-based technology company 3M has awarded a significant philanthropic research grant of $400,000 (1.36 million NIS) to the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University to advance scientific knowledge in the global response to the COVID-19 pandemic. The grant from 3M, which bases its Israel operations in Herzliya, is part of a $5 million initiative to support research programs with a focus on treatments and vaccine development for COVID-19 at leading educational establishments around the world. TAU secured the funding through an international competitive process; this reflects the high esteem in which the University’s scientific research programs are held. The grant was disbursed via 3M’s grant-making partner, GlobalGiving, to ensure thorough vetting, due diligence and reporting. The research project is being led by Professor Jonathan Gershoni, a renowned expert in viral pathogens, who said: “Publication of the SARS CoV2 genome on January 9, 2020, launched the race for a COVID-19 vaccine. Tens of vaccine candidates have already entered clinical trials, the leaders of which are actively recruiting thousands of volunteers worldwide for phase III efficacy trials. All these efforts use the viral spike protein as their vaccine’s active ingredient. This relatively large protein is made up of 1200 amino acids arranged in groups of three, decorating the virus with a crown-like appearance. “The spike protein presents many targets that have evolved to confuse and distract our immune system and to steer us away from the virus’ most vulnerable soft spot, its receptor-binding motif (RBM). In order for the virus to successfully infect us and cause COVID- 19, it must first latch onto a unique protein, the ACE2 receptor, which is present on the surface of our lung cells. For this, the viral RBM, a tiny but highly complex structure, must detect ACE2, bind to it and mediate infection. A vaccine that exclusively targets the RBM should be extremely potent in affording maximal protection against SARS CoV2 by stimulating our immune system in the most efficient and cost-effective way. “We have developed a novel patented technology to ‘surgically’ isolate the RBM from the rest of the spike protein. This grant from 3M will significantly enhance our efforts to produce a highly focused, potent and especially safe vaccine for COVID 19,” he added.

^{Prof. Gershoni’s Lab team (Photographer: Moshe Bedarshi)} This study is anchored in more than 30 years of research on the interaction of RNA viruses with their receptors and the immune response against them, noted Professor Tal Pupko, Head of the Shmunis School at TAU. “The 3M grant will dramatically accelerate the pace of research for overcoming COVID-19,” said Professor Pupko, adding that Tel Aviv University was particularly proud to be included in this important global initiative by 3M. “Science is at the heart of 3M and we are committed to advancing the rapid study of this virus as part of our continued effort to combat the COVID-19 pandemic,” said Isabelle Zadikov-Carp, 3M Israel Country Leader. “It’s important that 3M holds true to its core values by supporting our communities and improving lives. We hope that the grant to TAU will facilitate the development of an effective vaccine and we will be keenly following the progress and outcomes of Professor Gershoni’s research with interest.” Featured image: Professor Jonathan Gershoni (Photographer: Moshe Bedarshi)

TAU Inaugurates Shmunis School of Biomedicine and Cancer Research

Written by AUFTAU on 8 September 2020. Posted in Newsroom.

School is funded with a generous gift from the Shmunis family for research and improved treatments for cancer, COVID-19, and other diseases Tel Aviv University inaugurated the Shmunis School of Biomedicine and Cancer Research, in the presence of Israel’s Minister of Science and Technology Izhar Shay and benefactors Vlad and Sana Shmunis, online, via RingCentral. The new School, part of the George S. Wise Faculty of Life Sciences will enable a leap in biomedical research. The School’s 300 researchers, students and staff in the fields of cancer research, cancer immunity, bioinformatics, microbiology, biotechnology, and more, will work to identify mechanisms that drive cancer and other diseases. Moreover, they will develop new pharmaceuticals and improve patients’ quality of life. This will be achieved through multidisciplinary collaborations and novel research approaches, such as single cell sequencing and bioinformatics. Vlad and Sana Shmunis expressed hope that their gift will help strengthen Israel’s standing as a global leader in cancer and molecular biomedical research. “In supporting TAU, we firmly believe that we have found an ideal partner to move the needle towards curing cancer and other terrible diseases,” said Vlad Shmunis, Chief Executive Officer and Founder of RingCentral, Inc. “Cancer is a disease that has unfortunately touched our family and far too many other families. We hope that our gift to TAU will … improve the lives of people in Israel and around the world.” The new partnership will enable the University to recruit the finest researchers and award the annual Shmunis Fellowships to exceptional PhD students. The School will also collaborate with leading academic institutions and host Shmunis Visiting Scholars and international conferences.

Recent Shmunis School achievements:

The Gershoni Lab was awarded a US patent for a novel vaccine against the coronavirus
The Stern Lab‘s genetic sequencing of the coronavirus tracked the spread of COVID-19 in Israel
The Ehrlic Lab is developing virus-based immunotherapies for cancer
The Lederkremer Lab developed a therapeutic approach for Huntington’s disease, for which no treatment exists

“I am grateful to the Shmunis family for their important and generous gift,” said Prof. Ariel Porat, President of Tel Aviv University. “Meeting high standards of other renowned centers for cancer research around the globe, the School will be a hub for the brightest Israeli and international researchers to join as faculty.” This is the Shmunis family’s second major donation to the University. They founded the Shmunis Family Anthropology Institute in 2018 dedicated to the study of the ancient past. The Institute conducts numerous cutting-edge research projects in anthropology and archaeology on campus, helping to shed light on the origins of humankind. Featured image: Prof. Ariel Porat, TAU President, and Prof. Tal Pupko, head of the Shmunis School, at the Shmunis School Inauguration Ceremony. Photo: Chen Galili.

Physical exercise can help improve both physical and mental health

Written by AUFTAU on 1 September 2020. Posted in Newsroom.

Researchers at Tel Aviv University have examined the connection between adolescents’ mental resilience and their participation in sports programs during the coronavirus pandemic. The researchers found that adolescents who continued to work out in a group context during the lockdown were more mentally resilient than their peers – even though the practice sessions were conducted online. The study – the only one of its kind in the world to focus on adolescents – was conducted by Dr. Keren Constantini, Irit Marcus, Dr. Naomi Apple, Dr. Ronit Jakobovitch, Dr. Iftach Gafner and Dr. Shahar Lev-Ari, and its results were presented at a joint conference of the Schools of Public Health Organization, the Israel Association of Public Health Physicians and the Sports Physicians Association.

“We conducted the study during the general lockdown,” says Dr. Lev-Ari, Head of the Department of Health Promotion at Tel Aviv University. “Some organizations and gyms had suspended their sports programs, but others – like the educational sports organization Chamesh Etzbaot (Five Fingers), adopted an online format, mostly through Zoom. We were interested in checking whether online activities helped build adolescents’ physical and mental resilience. To do this we compared two groups: adolescents who continued to practice in an online group context, and their peers who exercised on their own during the lockdown.”

For this purpose, Dr. Lev-Ari and his team conducted an online survey designed to test resilience levels, health behaviors and risk perceptions of 473 adolescents who had been enrolled in organized sports programs before the coronavirus outbreak. Their findings were statistically significant: Adolescents who continued to participate in sports programs through an online format during the lockdown actually practiced more, and consequently exhibited higher levels of resilience, had better self-esteem and higher morale, and expressed fewer concerns about the pandemic.

“We found that adolescents who continued to take part in their sports programs through the internet practiced more – 242 minutes of practice per week vs. only 191 minutes for adolescents who worked out on their own,” explains Dr. Lev-Ari. “But this only accounts for the physical resilience. In addition, there is the aspect of mental resilience: a person’s ability to cope with difficulties, burdens and stress. This has to do with an element of personal endurance that stems from personality, as well as various acquired elements – like the size of the ‘battery’ I have for withstanding pressure, and how quickly I can recharge it.”

To test the adolescents’ mental resilience, the researchers compared the results of those who practiced in an online group with the results of those who continued to work out on their own during the lockdown, based on validated questionnaires such as the Connor-Davidson Resilience Scale. These questionnaires include statements like “I tend to bounce back easily from illness or difficulty”, “I don’t despair easily when I fail” and “I see the amusing side of things” – with each respondent ranking how true the statement is for him/her on the given scale.

“The results were unequivocal, in all measures,” says Dr. Lev-Ari. “The adolescents who continued their sports program exhibited higher spirits, less anxiety about themselves and their families, and lower levels of stress – even though their practice sessions continued through Zoom. Moreover, these adolescents were more aware of the importance of organized sports, especially at this time. 84% of the adolescents who participated in sports said that the continued practice sessions helped them cope with negative feelings and low spirits during the lockdown; 55% indicated that their contact with the coach served as a meaningful source of support. Our study proves the importance of continued activities in organized sports programs in these challenging times of the COVID-19 pandemic, and similar conclusions can certainly be deduced with regard to other social organizations as well, such as youth movements.”

New school for Biomedicine and Cancer Research at Tel Aviv University

Written by AUFTAU on 14 August 2020. Posted in Newsroom.

Israel’s Minister of Science and Technology Yizhar Shay and TAU President Prof. Ariel Porat will attend the inauguration ceremony of the Shmunis School of Biomedicine and Cancer Research, to be held on Wednesday, August 12, 2020.

The School belongs to the George S. Faculty of Life Sciences and the generous donation will enable a leap in groundbreaking research. At the Shmunis School researchers will be able to identify mechanisms that drive cancer and other diseases, developing new pharmaceuticals and improving patients’ quality of life. This will be achieved through multidisciplinary collaborations and novel research approaches, such as single cell sequencing, proteomics, lipidomics and bioinformatics.

In addition, the new partnership will enable the University to recruit the finest researchers into its faculty, attract the best post-doctoral candidates, award the annual Shmunis Fellowships to exceptional PhD students, and more. The School will also collaborate with many leading academic institutions and host Shmunis Visiting Scholars and international conferences.

Create an important impact

Yizhar Shai, Israel’s Minister of Science and Technology: ”Tel Aviv University is one of the leading academic institutions in Israel and the inauguration of the Shmunis School of Biomedicine and Cancer Research proves that the university also made an international name for itself. Connections like that, between the academia and industry’s needs, create an important impact on academic institutions, the students passing through them, and the whole Israeli economy. I congratulate the Shmunis family for the most welcome donation which promotes cancer research. I have no doubt that the research and the developments from this institution will be Israel’s pride and joy.”

Prof. Ariel Porat, President of TAU: “I am grateful to the Shmunis family for their important and generous gift. The funds will enable researchers at the School to work at the forefront of global science and to develop insights leading to the development of new technologies and drugs in the battle against cancer and other serious diseases.”

Vlad and Sana Shmunis expressed the hope that the gift will help strengthen Israel’s standing as a global leader in cancer and molecular biomedical research. Vlad Shmunis: “My wife Sana and I are very happy that we can take part in supporting frontline research. Cancer is a disease that has unfortunately touched our family and far too many other families around the world. We hope that our gift to TAU will significantly advance research and treatment of cancer and other serious diseases to improve the lives of people in Israel and around the world.”

Featured image: TAU President Prof. Ariel Porat and Israel’s Minister of Science and Technology Izhar Shay (Photo Credit: Chen Galili)

TAU Researcher Invents Environmentally-Friendly Sanitizer

Written by AUFTAU on 12 August 2020. Posted in Newsroom.

Tag: Medicine

Immunity Memory Cells Stay Stable Over Time After Recovery From COVID-19

They don’t forget so quickly

Concern over problem in reliability results in serological surveys

Researchers Identified the Genetic Causes of Inherited Hearing Loss in the Jewish Population of Israel

New Program Fosters Well-Rounded STEM Graduates

Google Awards Competitive Grant to Tel Aviv University for COVID-19 Research

Targeting Melanoma

In search of an optimal ratio

Promising results

TAU Wins 3M Grant to Accelerate COVID-19 Vaccine Development

TAU Inaugurates Shmunis School of Biomedicine and Cancer Research

Physical exercise can help improve both physical and mental health

New school for Biomedicine and Cancer Research at Tel Aviv University

TAU Researcher Invents Environmentally-Friendly Sanitizer

Victoria

New South Wales

Western Australia

Tag: Medicine

Joint research between TAU and Hasharon Hospital (Rabin Medical Center) proposes the new possibility

They don’t forget so quickly

Concern over problem in reliability results in serological surveys

A New Gene for Human Deafness Found in a Family in Israel

The 25th gene

The grant is for high-impact research using Data Science and Artificial Intelligence (AI) to combat the coronavirus

TAU researchers create a nanocarrier that selectively delivers two medications and releases them simultaneously at the malignant target

In search of an optimal ratio

Promising results

Grantee Professor Jonathan Gershoni aims to block the coronavirus by targeting its most vulnerable spot

Participating in online sports programs during the COVID-19 pandemic improves adolescents’ psychological resilience

The school, funded by a generous endowment from the Shmunis Family, aims to research and improve treatments for cancer, COVID-19 and other diseases

Create an important impact

Innovative method to convert waste into disinfectant is a pandemic game-changer

Victoria

New South Wales

Western Australia

The 25^th gene